UDK: 616.233-085.31:614.2

COMPARATIVE ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH ISCHEMIC HEART DISEASE WITH CONCOMITANT OBSTRUCTIVE PULMONARY DISEASES UPON ADMINISTRATION OF CORAXAN (IVABRADINE) AND ISOPTIN SR (VERAPAMILE SR)

O. V. Magnitskaia, J. V. Likhodeeva, A. I. Malakhov, A. N. Podolskaia

Кафедра клинической фармакологии и интенсивной терапии с курсами клинической фармакологии факультета усовершенствования врачей и клинической аллергологии ВолГМУ

Abstract

A simple parallel group randomized investigation was performed. According to the MOS SF-36 data both ivabradine (13,75 mg/day) and verapamile SR (330 mg/day) have improved quality of life (QL) of postMI silent ischemic patients with stable angina (class I-II) and concomitant controlled/partly controlled bronchial asthma or moderate/severe chronic obstructive pulmonary disease. Ivabradine vs verapamile SR more significantly improved physical functioning, problems with work resulting from physical health, general health assessment, social functioning and mental health. Finally ivabradine more significantly increased Physical Component Summary (PCS). According to the SAQ data both drugs have demonstrated the same improvement of CHD-specific QL.

Keywords

coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), asthma, quality of life, MOS SF-36, SAQ, ivabradine, verapamile.

Contacts

Магницкая Ольга Валерьевна — к. м. н., ассистент, докторант кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ, e-mail: magol.73@mail.ru